In support of this idea, a post hoc analysis of Comparison of Age-related Macular Degeneration Treatments Trials (CATT) indicates significant occurrence of CNV-associated scars in response to anti-VEGF monotherapy, when assessed at a 2-year time point (Daniel et al., 2014). The gene discussed is VEGFA; the disease is age-related macular degeneration.